Minneapolis, MN Clinical Trials Report — May 2026

For Minneapolis residents interested in contributing to medical research, May 2026 presents a mix of urgent opportunities and promising new studies. With 59 clinical trials in Minneapolis scheduled to conclude enrollment within the next 90 days, prompt action is key for those looking to participate.

Among these rapidly closing trials, 10 are still actively seeking healthy volunteers, offering a chance to contribute to science without needing a specific medical condition. This urgency highlights a window of opportunity before these studies finalize their participant groups.

Upcoming Deadlines for Diverse Conditions

Patients with specific health conditions should also note the trials nearing their enrollment deadlines. Conditions with trials closing soon include:

• Opioid use disorder (2 trials)
• Ovarian cancer (2 trials)
• Traumatic brain injury (2 trials)
• Acute infection (1 trial)
• Acute lymphoblastic leukemia (1 trial)
• Acute myeloid leukemia (1 trial)
• Acute limb ischemia (1 trial)
• Advanced solid tumor (1 trial)
• Age-related macular degeneration (1 trial)
• ALS-frontotemporal dementia (1 trial)

New Research Horizons in Minneapolis

This month, Minneapolis welcomed 15 new clinical trials, an increase from the 11 trials that opened in April 2026. This brings the total number of actively recruiting trials in Minneapolis, MN, to 885 across 255 research facilities, demonstrating a vibrant research landscape.

May's new trials include several notable studies from major sponsors, offering participants access to cutting-edge research:

• Novo Nordisk A/S is sponsoring a significant Phase 3 study, NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This large trial, aiming for 2,500 participants, investigates the safety and effectiveness of CagriSema for weight loss in individuals with obesity, with or without type 2 diabetes.
• For healthy adults with tick exposure, Tarsus Pharmaceuticals, Inc. is leading NCT07562087, "A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure." This Phase 2 study plans to enroll 700 healthy adult participants to evaluate the safety, tolerability, and pharmacokinetics of an orally administered compound.
• Stephanie Di Stasi is sponsoring NCT07584252, "The Healing and Empowerment Actions for Recovery From Trauma (HEART) Trial." This study, with 804 participants, aims to determine if comprehensive psychosocial support improves outcomes for patients who sustain moderate to severe trauma requiring orthopedic surgery, as well as for their care-partners and healthcare workers.
• TearSolutions, Inc. is conducting NCT07568730, "A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis." This Phase 2 study, involving 54 participants, will evaluate the safety and effect of Lacripep on the ocular surface and visual function for individuals with Stage 1 Neurotrophic Keratitis.

New trials this month are addressing a variety of conditions, including acute myelogenous leukemia, astrocytoma, cardiac amyloidosis, and glioblastoma. One new trial specifically seeks healthy adult participants. Drug trials constitute the largest category of new studies, with 6 new drug trials, followed by 5 "other" types of studies and 3 device trials.

Opportunities for Healthy Volunteers

Individuals without a specific medical condition have valuable opportunities to contribute to research. Of the 15 new trials launched this month, 3 are actively seeking healthy volunteers. Overall, Minneapolis currently has 98 clinical trials recruiting healthy participants, providing numerous avenues for those interested in supporting medical advancements.

Minneapolis's Leading Research Institutions

Minneapolis is home to several prominent research institutions that consistently lead in the volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Minnesota (285 trials)
• Abbott-Northwestern Hospital (91 trials)
• Hennepin County Medical Center (78 trials)
• University of Minnesota/Masonic Cancer Center (43 trials)
• Health Partners Inc (41 trials)
• Children's Hospitals and Clinics of Minnesota - Minneapolis (27 trials)
• Minneapolis Heart Institute Foundation (25 trials)
• Minneapolis VA Health Care System, Minneapolis, MN (22 trials)

These institutions offer a broad spectrum of research, from comprehensive university-led studies to specialized research in cardiology at the Minneapolis Heart Institute Foundation and pediatric care at Children's Hospitals and Clinics of Minnesota.

Expanding Your Search: Nearby Minnesota Cities

While Minneapolis offers a wide array of clinical trial opportunities, individuals may also find options in other communities within Minnesota. Cities with active trials include Rochester (16 trials), Dilworth (1 trial), Golden Valley (1 trial), Richfield (1 trial), and Saint Paul (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 15 new trials launched this month, 14 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, and 1 trial is male-only. Academic institutions continue to play a vital role in Minneapolis's research ecosystem, with the University of Minnesota (5 trials) and Masonic Cancer Center, University of Minnesota (2 trials) sponsoring the most new studies. Industry sponsors like Novo Nordisk A/S (1 trial), Tarsus Pharmaceuticals, Inc. (1 trial), and AstraZeneca (1 trial) are also driving significant research efforts.

As we continue through spring, Minneapolis's dynamic research community will keep advancing medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.